Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) drives global healthcare innovation through its pharmaceutical, medical technology, and consumer health divisions. This dedicated news hub provides investors and industry professionals with essential updates on regulatory developments, research breakthroughs, and strategic initiatives from one of healthcare's most diversified leaders.
Access real-time press releases and curated analysis covering FDA approvals, clinical trial results, and market expansion efforts. Our repository simplifies tracking JNJ's progress in oncology, immunology, and surgical advancements while maintaining perspective on its long-term corporate strategy.
Key updates include earnings disclosures, product pipeline milestones, and partnership announcements that demonstrate JNJ's commitment to addressing complex health challenges. Bookmark this page for streamlined access to verified information supporting informed decisions about this Dow Jones Industrial Average component.
On October 14, 2021, lawyers representing over 30,000 women filed lawsuits against Johnson & Johnson (JNJ) regarding cancer claims tied to its talc body powders. They criticize J&J's bankruptcy move to evade legal accountability as hypocritical and unjust, especially given the company's substantial profits. J&J’s new subsidiary, LTL Management LLC, has filed for bankruptcy to manage these claims, proposing a $2 billion settlement fund despite total liabilities estimated at over $25 billion. The legal battle raises concerns for pending trials and could prolong suffering for affected patients.
Johnson & Johnson (NYSE: JNJ) announced that LTL Management LLC, a newly formed subsidiary, has filed for voluntary Chapter 11 bankruptcy to manage claims related to cosmetic talc litigation. This bankruptcy aims to provide an equitable resolution for current and future claimants. JNJ will fund LTL with a $2 billion trust and royalty revenue streams worth over $350 million. The company maintains its stance on the safety of its talc products, citing favorable jury trial outcomes. All cosmetic talc litigation cases will be stayed pending the bankruptcy proceedings.
Johnson & Johnson (NYSE: JNJ) is set to host a Business Review for the investment community on November 18, 2021. The event will offer insights into the company's Pharmaceuticals business, highlighting its unique strategy and strong pipeline for growth. Participants can expect a detailed overview of six therapeutic areas, live sessions with executives, and Q&A opportunities. Registration opens on November 1. A replay of the event will be available after it concludes.
Johnson & Johnson (NYSE: JNJ) appointed Jessica Moore as Vice President of Investor Relations, effective November 1, 2021. Moore, with 20 years of financial experience, most recently served as CFO for the Janssen Pharmaceutical business in EMEA. She will report to Joseph Wolk, CFO, and is expected to enhance communication of JNJ's strategies to investors. Moore holds degrees in Finance and Accounting and an MBA. This leadership change aims to leverage her expertise to positively impact JNJ's financial narrative.
Johnson & Johnson (NYSE: JNJ) announced the retirement of Dr. Paul Stoffels, Vice Chairman and Chief Scientific Officer, effective December 31, 2021. Dr. Stoffels has been pivotal in enhancing the company's innovation pipeline, leading initiatives that delivered over 25 new medicines, some of which are on the WHO's Essential Medicines List. He also played a key role in developing the COVID-19 vaccine and in global health advocacy. Johnson & Johnson aims to continue his legacy of innovation and public health commitment under new leadership.
Johnson & Johnson (NYSE: JNJ) will participate virtually in the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021. Ashley McEvoy, Executive Vice President and Worldwide Chairman of Medical Devices, will represent the company in a session at 11:20 a.m. ET. This event will be accessible to investors and interested parties via the Johnson & Johnson website. A webcast and podcast replay will be available about 48 hours post-event.
For more details, visit www.investor.jnj.com.
On October 6, 2021, Janssen Pharmaceutical Companies of Johnson & Johnson revealed groundbreaking preclinical data in Nature, showcasing a novel antiviral compound that may treat all dengue fever serotypes. The compound operates by obstructing key viral proteins, inhibiting replication, and demonstrating efficacy in both prevention and treatment settings. As dengue affects up to 400 million people annually, this advancement marks a significant step in addressing a critical public health issue. Janssen aims to escalate the compound's clinical development to deliver impactful solutions for at-risk communities.
Johnson & Johnson (NYSE: JNJ) announced the submission of data to the FDA for a booster shot of its COVID-19 vaccine for individuals aged 18 and older. Results from the Phase 3 ENSEMBLE 2 study show that a booster administered 56 days after the primary dose offers 94% protection against symptomatic COVID-19 and 100% against severe/critical cases. Additionally, Phase 1/2a data indicates a nine-fold increase in antibody levels after a booster at six months. The company plans further submissions to global health authorities to support vaccine administration strategies.
On September 21, 2021, Johnson & Johnson (NYSE: JNJ) shared new data affirming that its COVID-19 vaccine provides strong and long-lasting protection. A real-world effectiveness study indicated an efficacy rate of 79% for infections and 81% for hospitalizations. Additionally, a booster shot significantly enhanced protection, offering 94% efficacy against symptomatic COVID-19. The booster also heightened antibody levels by up to twelve times. The company has communicated these findings to regulatory agencies, including the FDA and WHO, as part of ongoing efforts to combat the pandemic.
